Febrile seizures, familial, 8
MONDO:0011891A childhood absence epilepsy that is characterized by mutations in the GABRG2 gene, which cause a spectrum of seizure disorders, ranging from early-onset isolated febrile seizures (FS) to childhood absence epilepsy (CAE) to generalized epilepsy with febrile seizures plus, type 3 (GEFS+3), which tends to represent a more severe phenotype.
Also known as: GABRG2 childhood absence epilepsy, GABRG2 generalised epilepsy with febrile seizures plus, GABRG2 generalized epilepsy with febrile seizures plus, childhood absence epilepsy caused by mutation in GABRG2, generalised epilepsy with febrile seizures plus caused by mutation in GABRG2, generalised epilepsy with febrile seizures plus, type 3, generalized epilepsy with febrile seizures plus caused by mutation in GABRG2, generalized epilepsy with febrile seizures plus, type 3
8 clinical trials for this condition and its sub-types, 0 tagged with Febrile seizures, familial, 8 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC